HUTCHMED (China) Limited
HKSE: 0013.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Chig Fung Cheng
- Employees
- 1,811
- Headquarters
- Hong Kong, Hong Kong SAR China
- IPO year
- 2021
- Market cap
- HK$18.1B
- Website
- https://www.hutch-med.com
Loading 0013…
Loading profile data…Frequently asked questions about 0013
What does HUTCHMED (China) Limited (0013.HK) do?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
Where does 0013.HK trade?
HUTCHMED (China) Limited (0013.HK) trades on the Hong Kong Stock Exchange.
What sector is 0013.HK in?
HUTCHMED (China) Limited (0013.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of HUTCHMED (China) Limited?
Chig Fung Cheng is the chief executive officer of HUTCHMED (China) Limited (0013.HK).
Where is HUTCHMED (China) Limited headquartered?
HUTCHMED (China) Limited is headquartered in Hong Kong SAR China.
Does 0013.HK pay a dividend?
HUTCHMED (China) Limited (0013.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0013.HK go public?
HUTCHMED (China) Limited (0013.HK) completed its initial public offering in 2021.